Introduction
Elevated serum uric acid levels result in various diseases such as gout, renal disease, and cardiovascular disease (1-5). Serum uric acid levels and prevalence of hyperuricemia increased with aging and also in postmenopausal women (6) (7) (8) . Increased uric acid also triggers endothelial dysfunction, which leads to metabolic syndrome and cardiovascular diseases (9) (10) (11) (12) (13) (14) . In the other hand, abdominal obesity, atherogenic dyslipidemia, insulin resistance, aging and hormonal imbalance are the risk factors for metabolic diseases, and patients with metabolic syndrome can have hyperuricemia and hypercholesterolemia (15) (16) (17) (18) , suggesting the relationship in the regulation of uric acid and cholesterol.
However, its precise mechanism has been unknown.
Uric acid is produced in the liver by xanthine oxidoreductase (XOR) and excreted to urine. The excretion of uric acid is regulated by several uric acid transporters, such as urate transporter 1 (URAT1)/SLC22A12, ATP-binding cassette sub-family G member 2 (ABCG2)/ABCG2 and glucose transporter 9 (GLUT9)/SLC2A9 (19) (20) (21) (22) . In the proximal tubular (PT) cells, apical urate transporters form a super-molecular structure called urate transportsome, which are organized by a PDZ scaffold (23). Uric acid reabsorption transporters play an important role in regulating serum uric acid levels, and inhibitors of these transporters such as lesinurad and dotinurad attenuate hyperuricemia (24) (25) (26) (27) .
Previously, we found 27-hydroxycholesterol (27HC) function as an endogenous selective estrogen (ER) modulator (SERM) and promotes atherosclerotic lesion development in an ER-depending manner (28) . While estrogen acts as an agonistic and antagonistic on ER in a tissue-and cell-context manner (29, 30) . Serum 27HC and cholesterol levels are positively correlated, and serum 27HC levels are also elevated with particularly after 30 years old (29, (31) (32) (33) ,. Furthermore, circulating 27HC levels in premenopausal women are lower than in men, and are increased after menopause (29, 31) . In this study, we examined the role of 27HC in renal function, and found that 27HC activates URAT1/SLC22A12 expression via ER using single-cell RNA-sequencing (scRNA-seq), gene promoter analysis, cell culture assays, histology, and kidney organoid assays.
Results

Uric acid reabsorption transporters are expressed in kidney PT cells
To analyze the transcription of uric acid transporters at single-cell resolution, we performed the analysis on publicly available scRNA-seq data of human adult kidneys (34) (Fig. 1 and S1 ). We found that uric acid reabsorption transporters OAT4/SLC22A11, URAT1/SLC22A12, and OAT10/SLC22A13, displayed similar transcription patterns to the markers of proximal tubular cells, cubilin (CUBN), low density lipoprotein-related protein 2 (LRP2), and solute carrier family 5 member 12 (SLC5A12). (Fig. 1C ).
URAT1, OAT4, and OAT10 are expressed only limited cells in the PT
After glomerular filtration, 90% uric acid is reabsorbed (35) . Considering the importance of uric acid efflux/reabsorption in the PT region, we performed scRNA-seq analysis on the distribution of uric acid transporters. Although the expression of secretion uric acid transporters was abundant except for ABCG2/ABCG2 in the PT region ( Fig. S4) , only a small number of cells express reabsorption transporters URAT1/SLC22A12-, OAT4/SLC22A11-, or OAT10/SLC22A13-positive cells were present in only 9.2%, 26.5%, or 2.1%, respectively, in the PT cells ( Fig. 2A-F) . Our observations suggest a specific transcriptional regulation that is involved in the expression of uric acid reabsorption transporters.
URAT1 is uniquely regulated from other reabsorption uric acid receptors
To investigate the factors that regulate the three reabsorption transporters, URAT1/SLC22A12, OAT4/SLC22A11, and OAT10/SLC22A13, we first analyzed the correlation of their gene expression.
Among these genes, OAT4/SLC22A11 and OAT10/SLC22A13 showed relatively correlated gene expression patterns ( Fig. 3A-C) . However, URAT1/SLC22A12 gene expression showed less correlation with the other reabsorption transporters, suggesting that URAT1/SLC22A12 expression may have different regulation from the regulation of the other two transporters. Next, we compared the gene promoter region sequences. The promoter sequence of URAT1/SLC22A12 was distant phylogenic relationship with OAT4/SLC22A11 or OAT10/SLC22A13, further supporting the unique transcriptional regulation of this gene from the other two ( Fig.3D ). We also analyzed the amino acid sequences of the three reabsorption transporters share closer phylogenic relationship ( Fig.3E and S2A ). In contrast, from structural prediction, phenylalanine 365 (F365) in URAT1/SLC22A12 has been previously found to be involved in the recognition of uric acid (36) , while the conserved site in the other SLC22A transporters is tyrosine, suggesting that URAT1/SLC22A12 has a higher binding affinity for uric acid (36) (Fig. S2B ). These results suggest that the gene expression of URAT1/SLC22A12 is uniquely regulated from other reabsorption uric acid transporters.
URAT1/SLC22A12 is regulated by 27HC through ERE gene promoter sequences
To find the key factors for the different transcriptional regulation of reabsorption uric acid transporters, we further analyzed their gene promoter regions. Since increased uric acid is associated with metabolic condition and sex hormone status, we focused whether the gene promoter region has transcription factor motifs related to metabolic or sex hormone-regulated transcription factors. We found that the URAT1/SLC22A12 gene promoter region had nine ERE (estrogen response element) sequences and also the highest ERE value among these three transporter genes (Fig. 4A , 4B and S3). ER binds to EREs and regulate the transcription. ESR1, which encodes estrogen receptor α, but not ESR2, was abundant in the PT cells ( Fig. S5A) (34) . Thus, we investigated the regulation of URAT1/SLC22A12 through the identified EREs. To investigate which ERE regulates the URAT1/SLC22A12 transcription activity responding to ERs, we designed a construct that indicates URAT1/SLC22A12 promoter activity by luciferase expression ( Fig. 4C and D) .
Since there is a correlation between serum uric acid levels and metabolic condition, and also 27HC act as an endogenous SERM and regulates transcriptional activities through EREs (33, 37), we examined the effects of 27HC on URAT1/SLC22A12 gene promoter activity. Gene promoter activity of URAT1/SLC22A12 was increased by 27HC in HepG2 cells ( Fig. 5A ). In contrast, 3β-hydroxy-5cholestenoic acid, a metabolite of 27HC, did not increase URAT1/SLC22A12 gene promoter activity ( Fig.   5B ), suggesting that 27HC itself, upregulates URAT1/SLC22A12 gene transcription. To further determine the impacts of 27HC in URAT1/SLC22A12 promoter region, we treated cells with an ER antagonist, ICI 182,780 (38). ICI 182,780 alone decreased the URAT1/SLC22A12 gene promoter activity, indicating that it inhibited gene promoter upregulation through endogenous factors (Fig. 5C ). The effect of 27HC was suppressed by a co-treatment with ICI 182,780 ( Fig. 5D ), suggesting that 27HC increased URAT1/SLC22A12 gene transcription via ER activity. Importantly, ERE mutation decreased the baseline of gene promoter activity ( Fig. 5E ), indicating that ERE sequence plays a major role to activate URAT1/SLC22A12 transcription. ERE mutation also inhibited gene promoter upregulation of 27HC ( Fig.   5E ). These data showed that human URAT1/SLC22A12 gene promoter is regulated by 27HC via ER through estrogen response elements.
27HC increases URAT1/SLC22A12 expression in the kidney
Finally, to confirm above URAT1/SLC22A12 transcriptional regulation in organs, we employed mouse kidneys and human kidney organoids. 27HC is metabolized by CYP7B1, and the loss of Cyp7b1 in mouse results in elevated serum 27HC levels without affecting cholesterol and bile acid levels (39).
Therefore, we performed immunohistochemistry using kidneys from Cyp7b1 -/and wild-type mouse. URAT1/SLC22A12 protein expression was observed in PT region and, the expression levels increased in male Cyp7b1 -/mouse ( Fig. 6A and B ). Interestingly, female Cyp7b1 -/mouse did not show URAT1/SLC22A12 expression levels ( Fig. S8A and B ), suggesting the involvement of sex hormone coregulation. Furthermore, we performed kidney organoid culture from human iPS cells to examine the effect by 27HC on the URAT1/SLC22A12 expression in human kidneys, because kidney organoids mimic human embryo kidney. 27HC increased URAT1/SLC22A12 gene expression in the kidney organoids ( Fig.   6C ), suggesting that its effects on URAT1/SLC22A12 expression is also observed in human kidneys.
Discussion
Our current study demonstrated that 27HC, an endogenous SERM, can increase serum uric acid levels by regulating the expression of URAT1/SLC22A12 and serum uric acid levels ( Fig. S8) . A high-fat diets and alcohol consumption are known to increase serum uric acid levels, and these factors are consequently considered to activate xanthine oxidoreductase by increasing purine. Although the expression of URAT1/SLC22A12 increased in hyperuricemia or obesity in animal models, there was limited information on the mechanism(s) by which URAT1/SLC22A12 expression is regulated (40-42). URAT1/SLC22A12 localizes on the apical membrane of proximal tubular cells and is deemed to be involved in both pre-secretary and post-secretary reabsorption (43, 44) . The distribution of URAT1/SLC22A12 on the proximal tubule remains controversial; one report showed its distribution on S1 and S3 segments (43) , while another group found the transporter on S1 segments only (44) . To transcriptionally characterize URAT1/SLC22A12-positive cells, we analyzed human adult kidney scRNAseq datasets (23) and identified the URAT/SLC22A12-positive cells at single cell resolution ( Fig. 2A and   B ). Most of filtered uric acid is reabsorbed from urine, and URAT1/SLC22A12 contributes to the reabsorption (35) . The importance of URAT1/SLC22A12 was demonstrated by using URAT1/SLC22A12 inhibitors dotinurad and lesinurad that decreased serum uric acid levels (24-26). Increased expression of URAT1/SLC22A12 was also been found in pathological rodent model (40-42). Initially, we hypothesized that the risk factor of various diseases would affect URAT1/SLC22A12 expression and increase the number of URAT1/SLC22A12-positive cells. Nonetheless, we found that the number of the URAT1/SLC22A12-positive cells was unexpectedly small (9.3%) ( Fig. 2A and 2B ). These results, together with the abundant expression of uric acid efflux transporters in the PT region, suggest that limited number of cells regulate uric acid reabsorption by changing the expression of URAT1/SLC22A12. URAT1/SLC22A12 gene promoter has nine EREs. ER regulates the transcriptional of its target gene through EREs. 27HC, an endogenous SERM, promotes atherosclerosis through its activation of proinflammatory processes that are mediated by ER. In this study, we found that 27HC also increases URAT1/SLC22A12 gene and protein expression. The upregulation URAT1/SLC22A12 gene promoter activity by 27HC was suppressed by both ICI 182,780, an ER antagonist, and mutation on the ERE sequences on the gene promoter region ( Fig. 5D and 5E ). The circulating level of 27HC is higher in men than in women and also increased with age (29, 31, 32) . Furthermore, in women the serum 27HC levels increase after menopausal that greatly lowers estrogen biosynthesis (31) . These trend resembles uric acid levels. In addition, the activity of kidney CYP7B1 decreases with age, which further increases local 27HC levels in the kidney (45) . Taken together with our results, it is suggested that the increment of the serum and kidney 27HC levels with age upregulates URAT1/SLC22A12 transcriptional activity and thereby increases serum uric acid levels (Fig. S9 ).
The 27HC is the most abundant oxysterol in human circulation, and its circulating levels are elevated with hypercholesterolemia and metabolic or cardiovascular dysfunction such as atherosclerosis.
Therefore, the expression of URAT1/SLC22A12 is elevated in obese and atherosclerosis condition, at least in part, by elevated 27HC levels. URAT1/SLC22A12 protein expression is increased in mice fed a high-fat diets and also in genetically modified obese (ob/ob-) mice (42). Although the previous report did not measure 27HC levels, 27HC may have had an impact on the expression of URAT1/SLC22A12. Urinary uric acid excretions were observed lower in obese people compared with people with normal body weight.
Additionally, body mass index is positively correlated to serum uric acid levels, suggesting that 27HC and URAT1 protein levels are increased in obese people, leading the increase in serum uric acid levels.
Abnormal levels of uric acid cause various diseases, such as gout, renal disease, and cardiovascular diseases. Based on our findings, it is plausible that elevated 27HC levels induce high serum uric acid levels and promote the related diseases. Our findings in this study highlight the importance of controlling serum uric acid and cholesterol levels, help to understand the correlation between hyperuricemia and metabolic syndrome, and also provide a potential therapeutic approach toward hyperuricemia-related diseases by modifying 27HC levels.
Materials and Methods
Single-cell RNA-sequencing analysis
Single-cell transcriptome analysis on the human adult kidney was performed using a dataset of single nucleus RNA-seq from a human adult kidney (GEO: GSE118184) (34) . Obtained digital gene expression matrix was processed for quality control, dimensionality reduction and cell clustering using Seurat (https://satijalab.org/seurat/) plug-in of R software (https://www.r-project.org/). Cells were filtered out as low-quality cells judging from unique feature counts and mitochondrial counts. After the filtration, we employed sctransform normalization (46, 47) . During the normalization, we removed the confounding sources of variation; mitochondrial mapping percentage, the total number of molecules and cell cycle heterogeneity. Principal component (PC) analysis using the function RunPCA generated clusters was conducted and the first top significant PCs were selected for two-dimensional Uniform Manifold Approximation and Projection (UMAP) with the methods of PCHeatmap, JackStrawPlot and PCElbowPlot.
Unsupervised clustering was done by the functions, FindClusters and RunUMAP at a resolution level of 0.8. Each cluster was identified using marker genes reported by a previous report (34) . The hierarchical clustering heatmap was generated using heatmap.2 function from the ggplot2 package with the average expression of each cluster against the marker genes. The dot-plot was generated with the average expression of each cluster against the marker genes.
Alignment of uric acid transporter
We identified the 1000bp upstream sequences in gene promoter region and amino acid sequences of human uric acid transporters (URAT1/SLC22A12, OAT4/SLC22A11, OAT10/SLC22A13, ABCG2/ABCG2, NPT1/SLC17A1, NPT4/SLC17A3, GLUT9/SLC2A9, OAT1/SLC22A6 and OAT3/SLC22A8) derived from the NCBI database. Multiple alignment was performed by MUSCLE. Phylogenetic tree was generated by ClustalW 2.0 using the Neighbor-Joining (NJ) method (48, 49) and DRAWTREE in PHYLIP software suite (50) .
Transcription factor (TF) search
We searched TF sites by using TFBIND (http://tfbind.hgc.jp/). Sequence Logo was made by Web Logo 3 (http://weblogo.threeplusone.com/.
ERE score
ERE score was defined as the calculated consensus score by TFBIND. ERE values were represented as multiplication of the ten-fold ERE scores. 
URAT1/SLC22A12 promoter cloning
ERE mutagenesis
All constructs were designed by SnapGene (GSL Biotech LLC). The ERE sequences of URAT1/SLC22A12 promoter region was amplified to get mutants using PrimeSTAR® Mutagenesis Basal Kit (Takara) with the following primers, ERE#1 primer F: aagcaggattcagtacaagggctcgcagtgcgt, primer R:
cgagcccttgtactgaatcctgcttaaaagcca, ERE#2 primer F: ccagacactgcagtatgagaggccatagctgag, primer R:
tggcctctcatactgcagtgtctggcctggaac, ERE#3 primer F: cagctgccagcagtacaagcccacacagagact, primer R:
tgtgggcttgtactgctggcagctgcccagccc.
Cell culture and generation of stable cell line
The human hepatocellular carcinoma cell HepG2 was purchased from Cellular Engineering Technologies, Inc. HepG2 was maintained in RPMI1640 medium (Nacalai, Japan). Theses media were supplemented with 10% fetal bovine serum, 100 U/mL penicillin, and 100μg/mL streptomycin. The cells were cultured under a humidified atmosphere containing 5% CO2 at 37°C. To generate a stable line, cells were seeded in six-well plate at 1.0 × 10 5 cells per well and transfected with linearized luciferase expression plasmid fused with URAT1/SLC22A12 gene promoter region using Lipofectamine 2000 (Invitrogen). At 24 hours after transfection, medium was changed to G418 (800 μg/mL)-containing medium. We selected the stably transfected cells by changing medium every day for 2 weeks.
URAT1/SLC22A12 luciferase assay
The luciferase activity was measured in WT and ERE mutant URAT1/SLC22A12 promoter stably expressing HepG2 cells using One-Glo EX Luciferase Assay System (Promega) according to manufacturer's instructions. Briefly, 24 hours after seeding stable cells in ninety-six well plates, we exposed cells with 27HC, 3β-hydroxy-5-cholestenoic acid or ICI 182,780 for 24 hours. Then, 80μL of One-Glo EX reagent was added in each well and incubated for three minutes to lyse cells. Finally, luciferase activity
was measured with a SpectraMax. All treatment experiments were performed in triplicate.
Kidney immunohistochemistry
Kidney samples were collected from 12 months old Cyp7b1 +/+ and Cyp7b1 -/mice on the C57BL/6
background. Collected samples were fixed in 4% formalin for 48 hours in 4 o C, processed, paraffin embedded, and cut into 6-μm thick sections. After rehydration, the sections were treated in the citrate buffer (pH=6) at 95 o C for ten minutes for antigen retrieval, followed by 10% goat serum (Life Technologies) at room temperature for one hour. Then, the sections were blocked using avidin/biotin blocking kit (Vector Laboratories) for 15 minutes, added anti-URAT1 antibody (Milipore Sigma, HPA024575, 1:500), and incubated for overnight. After washing the sections, they were blocked again using 3% hydrogen peroxidase (ThermoFisher Scientific), and incubated with biotinylated goat-anti-rabbit antibody (Vector Laboratories, BA-1000, 1:200) for one hour. The sections were visualized using avidin biotin complex kit (ABC kit, Vector Laboratories) and DAB Quanto chromogen (ThermoFisher Scientific), followed by counterstaining with Harris hematoxylin (ThermoFisher Scientific).
Image analysis
We performed the image analysis using Image J/Fiji and detected the proximal tubule and measured the max intensity of brush border membrane in the proximal tubular cells. 240 points per image were measured in a blind-manner.
Kidney organoid culture
Organoids differentiation induced from human pluripotent stem cells. Kidney organoids were generated from human induced pluripotent stem cell line CRL1502 according to our protocol (51) with some modification. Briefly, human iPS cells were treated with 8 µM CHIR99021 in APEL2 (STEMCELL Technologies) supplemented with 1% Protein Free Hybridoma Medium II (PFHM II, GIBCO) (basal medium) for 5 days, followed by FGF9 (200 ng/ml) and heparin (1 µg/ml) for another 2 days. Then, cells were collected and dissociated into single cells using trypsin. 0.25 x 10 6 of collected cells were spun down at 400 x g for 2 min to form a pellet and pellets were transferred onto a Transwell of 0.4 µm pore polyester membrane (#3450 Corning) to culture in liquid-air interfaces. Pellets were treated with 10 μM CHIR99021 in basal medium for 1hour, and then cultured with FGF9 (200 ng/ml) and heparin (1 µg/ml) for another 5 days, followed by another 13-15 days in basal medium. Organoids were treated with 10 µM 27HC for last 2 days before sampling (day25 -27 of differentiation).
Quantitative RT-PCR
Total RNA was extracted from organoids using Nucleo Spin (MACHEREY NAGEL) and cDNA was synthesized from 500 ng of total RNA using PrimeScript™ RT Master Mix (TAKARA BIO). We performed quantitative reverse-transcription PCR (qRT-PCR) with SsoAdvanced Universal SYBR Green Supermix (Bio-Rad Laboratories, Hercules, USA) and specific primers for qRT-PCR. We also run the reaction in triplicate and normalized the transcription of each gene to the mean of β-actin as a housekeeping gene and analyzed using the ΔΔCT method by StepOne Software Ver2.3. The primer sequences for qRT-PCR were designed by Bio-Rad (URAT1/SLC22A12; qHsaCID0011483, β-actin; qHsaCED0036269).
Statistics and data analysis
The result of the luciferase assay and quantitative RT-PCR was represented by the ratio of control mean.
The values obtained are described as means ± SEM. We performed student's t-test, a one-way ANOVA followed by Dunnett test or two-way ANOVA followed by Sidak's multiple comparisons test to determine the significance among groups. All statistical analysis was performed by GraphPad Prism7. scRNA-seq measures transcripts from both cytoplasm and nucleus, whereas single nucleus RNA-seq measures only nuclear transcripts. Nuclei contains only a fraction of total cell RNA. Although nuclear and cytoplasmic mRNAs are highly correlated (52) , some protein-coding mRNAs are retained in the nucleus (53) . Despite these differences, single-cell and snRNA-seq datasets predict cell types comparably with high concordance (54, 55). Matsubayashi, Sakaguchi et al. Figure 5 
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